Objective To observe the clinical efficacy and safety of Tofacitinib in the treatment of ankylosing spondylitis(AS)patients through real-world study,detect and analyze the expression and changes of related molecules in Janus protein tyro-sine kinase signalling pathway before and after Tofacitinib treatment.Methods To collect and analyze the clinical and laboratory data of AS patients who were hospitalized in our hospital from January 2020 to January 2021 and treated with Tofacitinib for 6 months.The mRNA and the protein expression levels of JAK3、STAT5a、STAT5b were detected by qRT-PCR and Western-Blot.Re-sults ①30 AS cases were included in the study,22 were male and 8 were female,with an average age of(35.73±9.41)years and an average course of disease of(10.98±8.46)years.(2)After treatment,BASDAI,BASFI,ASDAS,ESR and hsCRP in pa-tients with AS were significantly lower than those before treatment(P＜0.05).The levels of WBC,GR,GR％,PLT and ALP in AS patients decreased(P＜0.05),while the levels of LY％,ALB and DBIL increased(P＜0.05);③ After treatment,the mRNA expression levels of STAT5a and STAT5b in PBMCs and the protein expression levels of P-JAK3/JAK3,P-STAT5a/STAT5a,P-STAT5b/STAT5b were significantly lower than those before treatment(P＜0.05).Conclusion Tofacitinib is effective and safe for patients with AS with moderate to severe disease activity.After treatment,the expression mRNA and the protein expression levels of JAK3/STAT5 decrease significantly,indicating that Tofacitinib may play a role by inhibiting the JAK3/STAT5 pathway.
关键词
枸橼酸托法替布/强直性脊柱炎/真实世界研究/Janus激酶3/信号转导和转录激活因子5
Key words
Tofacitinib/ankylosing spondylitis/real-world study/Janus kinase 3/signal transducer and activator of tran-scription 5
维普
万方数据